Evidence map›Paper›PMID 33062295›Full record

ArticlePilot and feasibility studies2020

Feasibility study on pre or postoperative accelerated radiotherapy (POP-ART) in breast cancer patients.

Hans Van Hulle, Vincent Vakaet, Giselle Post, Annick Van Greveling, Chris Monten, An Hendrix, Koen Van de Vijver, Jo Van Dorpe, Pieter De Visschere, Geert Braems and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pilot and feasibility studies, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Hype or hope? A review of challenges in balancing tumor control and treatment toxicity in breast cancer from the perspective of the radiation oncologist.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Hans Van HulleDepartment of Human Structure and Repair, Ghent University, Ghent, Belgium.ORCID 0000-0002-4343-2407
Vincent VakaetDepartment of Human Structure and Repair, Ghent University, Ghent, Belgium.
Giselle PostDepartment of Human Structure and Repair, Ghent University, Ghent, Belgium.
Annick Van GrevelingDepartment of Radiation Oncology, Ghent University Hospital, C. Heymanslaan 10, 9000 Ghent, Belgium.
Chris MontenDepartment of Human Structure and Repair, Ghent University, Ghent, Belgium.
An HendrixDepartment of Human Structure and Repair, Ghent University, Ghent, Belgium.
Koen Van de VijverDepartment of Pathology, Ghent University Hospital, C. Heymanslaan 10, 9000 Ghent, Belgium.
Jo Van DorpeDepartment of Pathology, Ghent University Hospital, C. Heymanslaan 10, 9000 Ghent, Belgium.
Pieter De VisschereDepartment of Radiology and Nuclear Medicine, Ghent University Hospital, C. Heymanslaan 10, 9000 Ghent, Belgium.
Geert BraemsDepartment of Human Structure and Repair, Ghent University, Ghent, Belgium.
Katrien VandecasteeleDepartment of Human Structure and Repair, Ghent University, Ghent, Belgium.
Hannelore DenysDepartment of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.
Wilfried De NeveDepartment of Human Structure and Repair, Ghent University, Ghent, Belgium.
Liv VeldemanDepartment of Human Structure and Repair, Ghent University, Ghent, Belgium.
Ghent University Hospital · BEGhent University · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn early-stage breast cancer, the cornerstone of treatment is surgery. After breast-conserving surgery, adjuvant radiotherapy has shown to improve locoregional control and overall survival rates. The use of breast radiotherapy in the preoperative (preop) setting is far less common. Nevertheless, it might improve disease-free survival as compared to postoperative radiotherapy. There is also a possibility of downsizing the tumour which might lead to a lower need for mastectomy. There are some obstacles that complicate its introduction into daily practice. It may complicate surgery or lead to an increase in wound complications or delayed wound healing. Another fear of preop radiotherapy is delaying surgery for too long. At Ghent University Hospital, we have experience with a 5-fraction radiotherapy schedule allowing radiotherapy delivery in a very short time span.

methodsTwenty female breast cancer patients with non-metastatic disease receiving preop chemotherapy will be randomized between preop or postoperative radiotherapy. The feasibility of preop radiotherapy will be evaluated based on overall treatment time. All patients will be treated in 5 fractions of 5.7 Gy to the whole breast with a simultaneous integrated boost to the tumour/tumour bed of 5 × 6.2 Gy. In case of lymph node irradiation, the lymph node regions will receive a dose of 27 Gy in 5 fractions of 5.4 Gy. The total duration of therapy will be 10 to 12 days. In the preop group, overall treatment time is defined as the time between diagnosis and the day of last surgery, in the postop group between diagnosis and last irradiation fraction. Toxicity related to surgery, radio-, and chemotherapy will be evaluated on dedicated case-report forms at predefined time points. Tumour response will be evaluated on the pathology report and on MRI at baseline and in the interval between chemotherapy and surgery. DISCUSSION: The primary objective of the trial is to investigate the feasibility of preop radiotherapy. Secondary objectives are to search for biomarkers of response and toxicity and identify the involved cell death mechanisms and the effect of preop breast radiotherapy on the in-situ immune micro-environment.

Indexed as

Breast cancerNeo-adjuvant chemotherapyNeo-adjuvant radiotherapy

Identifiers

PMID33062295
PMCPMC7547514
OpenAlexW3092191994

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.